



Docket No. 55908 (46322)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: J. Schofield et al. EXAMINER: Maria Marvich  
SERIAL NO. 09/868,879 ART UNIT: 1636  
FILED: June 22, 2001  
ENTITLED: GLYCOSYL PHOSPHATIDYL INOSITOL SPECIFIC  
PHOSPHOLIPASE D PROTEINS AND USES THEREOF

COMMISSIONER FOR PATENTS  
P. O. Box 1450  
ALEXANDRIA, VA 22313-1450

**DECLARATION OF THOMAS RADEMACHER**  
**UNDER 37 C.F.R. §1.132**

SIRS:

1. I, **THOMAS RADEMACHER** declare and say that I am a resident of Great Britain. My residence address is Foxcombe, The Ridgeway, Boar's Hill, Oxford, OX2 5EY, United Kingdom.
2. I am a Professor of Molecular Medicine in the Department of Immunology and Molecular Pathology, Division of Infectious Disease, University College of London (England) School of Medicine. I have special experience and knowledge in the field of enzymology, particularly the relationship of certain enzymes and disease. My Curriculum Vitae is attached as **Appendix C**. It shows, among other things, that I have published more than one hundred and sixty nine (169) research papers. It further shows my expertise and experience in the fields of enzymology, human disease and related areas.
3. I am co-inventor of claims 1-45 of the above-identified patent application (subject application). I understand that claims 46-67 will be pending following submission of the

attached response, which I have reviewed. I personally performed and/or assisted in research leading to the claimed invention.

4. I have read the Office Action dated July 2, 2004 for the subject application ("Office Action"). I understand from that Office Action that the USPTO rejected claims 4, 7-10, 13-14, and 17-20 on grounds that they contain subject matter that was not described in my specification in such as a way as to enable one skilled in the field to make and use the claimed invention.

5. I am familiar with the disclosures of Torchilin and Lukyanov (DDT Vol. 8 (6): 259-266 "Torchilin"), and Meng and Deiry (*Gene Therapy of Cancer*, 1999, pg. 6, col. 1, "Meng") as cited by the USPTO at pgs. 8-9 of the Office Action.

6. However, I must respectfully disagree that the Torchilin and Meng references as relied on support the Office position that the invention of claims 4, 7-10, 13-14, and 17-20 is in an unpredictable field.

7. For example, Torchilin as relied on by the USPTO certainly does not exclude use of the glycosyl phosphatidyl inositol specific phospholipase D (GPI-PLD) enzyme in the claimed methods. Indeed, and as I understand the reference, it reports on the successful use of certain peptides and antibodies as promising therapeutics.

8. As I understand the Meng reference cited by the USPTO, it shows results from animal studies in which a virus (eg., adenovirus) was used to deliver an anti-cancer therapeutic. That information is not related at all to the claimed invention which involves, among other things, administering GPI-PLD to treat other indications such as diabetes. Meng certainly does not exclude use of the GPI-PLD enzyme according to the claimed methods.

9. Thus, as I understand the Torchilin and Meng references as relied on by the USPTO in the Office Action, they do not support the position set forth in the Office Action that the claimed invention is in an unpredictable field.

10. I must also disagree with the USPTO that the invention of claims 4, 7-10, 13-14, and 17-20 is not enabled by my patent specification. Indeed, it is my belief that the specification shows how to make and use the claimed invention.

11. For instance, I am familiar with unpublished research that was performed by me and my co-inventor. That work was conducted along lines of my patent specification and it showed, among other things, that administration of GPI-PLD lowered plasma insulin and raised blood glucose in hyperinsulinaemic and insulin-resistant mice (db/db and ob/ob genotype). These mice are recognized models of human disease, particularly diabetes and complications thereof. Importantly, the reduction in plasma insulin and increase in blood glucose levels seen in the mice are highly significant and indicative of a useful therapeutic. More particularly, the results are consistent with a new protocol for the treatment of hypoglycaemia including indications associated with diffuse hyperinsulinism and insulinomas.

12. Additionally, and in accord with the specification, a worker can administer the GPI-PLD enzyme to an animal in need of treatment in a variety of ways. These administration routes include, but are not limited to, injection routes. See the section entitled "Pharmaceutical Compositions" pg. 20, line 33 to pg. 24, line 20. In particular, the enzyme can be administered isotonicly using saline injection. See pg. 23, lines 30-33.

13. As the specification makes clear, the specific amount of the GPI-PLD enzyme to be administered will depend on parameters understood and accepted by workers in the field. These parameters include the nature and severity of the indication and the administration route selected. See pg. 24, lines 1-20. The severity of diabetes and related complications, for instance, are

known to vary among individual patients. A worker reading my patent specification would understand and appreciate these variables. With this knowledge in hand, they would certainly know how to administer the GPI-PLD enzyme to treat disease indications mentioned in my patent specification after reading it.

**14. Administration of GPI-PLD Enzyme Decreased Plasma Insulin in ob/ob Mice**

I obtained female ob/ob mice C<sub>57</sub>BL/6J obese (Lep<sup>ob</sup>/Lep<sup>ob</sup>) from Harlan Olac Ltd (Bicester, UK) and subjected them to a standard fasting regimen starting 60 minutes prior to the administration of GPI-PLD. Human serum GPI-PLD partially purified by the method of Rhode et al 2000 (Biol. Chem. 381, 471-485) and formulated along lines of my patent specification as an aqueous solution in 0.05 % Triton X-100 at a concentration of 1900 U/ml. The GPI-PLD enzyme was administered to the fasting ob/ob mice about 2 hours before intraperitoneal (i.p.) injection of 2 g of glucose/kg body weight (GTT or glucose tolerance test). Insulin levels were measured in plasma using a mouse insulin ELISA kit from MERCODIA AB, Sylveniusgatan 8A, S-754 50 Uppsala, Sweden. The graph provided in **Appendix A** shows, among other things, that administration of GPI-PLD substantially reduced plasma insulin in the mice. In the graph, data were normalized on the 0 h values and are the mean  $\pm$  SD of 8 observations. The symbol “\* “ indicates statistically significant differences. Insulin  $p=0.0224$  at 1h and  $0.0472$  at 3h.

**15. Administration of GPI-PLD Enzyme Increased Blood Glucose in ob/ob Mice**


I obtained female ob/ob mice C<sub>57</sub>BL/6J obese (Lep<sup>ob</sup>/Lep<sup>ob</sup>) from Harlan Olac Ltd (Bicester, UK) and subjected them to a standard fasting regimen starting 60 minutes prior to the administration of GPI-PLD. The GPI-PLD enzyme was obtained and formulated (as described previously) at a concentration of 1900 U/ml. The GPI-PLD enzyme was administered to the fasting mice about 1 hour before intraperitoneal (i.p.) injection of 2 g of glucose/kg body weight (GTT). Blood glucose levels were measured using an Espirit™ glucometer according to

procedures provided by the manufacturer. The graph provided by **Appendix B**, shows, among other things, that administration of GPI-PLD substantially increased blood glucose in the rats. Data in the graph were normalized on the 0 h values and are the mean  $\pm$  SD of 8 observations. The symbol “ \* ” indicates statistically significant differences. Glucose  $p > 0.05$  at 1h and  $p = 0.0144$  at 3h.

16. The data provided by **Appendices A and B** show, among other things, that the information found throughout my patent specification can be used to treat indications characterized by reduced levels of GPI-PLD such diabetes and complications thereof, liver dysfunction, and disorders involving pancreatectomies. This information is consistent with my patent specification that shows, among other things, how to use GPI-PLD enzyme to treat conditions characterized by reduced levels of the enzyme or which respond positively to that enzyme. For instance, the section under “Summary of the Invention”, pg. 20, line 33 to pg. 24, line 20; pg. 23, lines 30-33; and pg. 24, lines 1-20.


17. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dec 6, 2004  
Date

  
Thomas Rademacher


## APPENDIX A

### Administration of GPI-PLD reduces insulin in diabetic mice



## **APPENDIX B**

### **Administration of GPI-PLD increases blood glucose in diabetic mice**



### **APPENDIX C**

**Name:** Thomas W. Rademacher  
**National Status:** British Resident/U.S. Citizen  
**Telephone No (UK):**  
Office (0171) 504 9373  
Fax (0171) 504 9497  
e-mail: t.rademacher@ucl.ac.uk

#### **Current Appointment**

Professor of Molecular Medicine, Head - Molecular Medicine Unit  
Department of Molecular Pathology  
University College London Medical School  
Windeyer Building  
46 Cleveland St.  
London  
W1P 6DB

#### **Higher Education**

1968-72	University of Wisconsin Madison - <b>B.Sc.</b> characterisation of an iron sulfur metallo protein from the anaerobe Clostridium Pasteurianum"	Biochemistry cum laude - on "Isolation, purification and characterisation of an iron sulfur metallo protein from the anaerobe Clostridium Pasteurianum"
1972-76	University of Wisconsin Medical School - <b>M.D.</b>	National Medical Board Certificate
1976-80	University of Wisconsin Madison - <b>Ph.D</b> Biochemistry	Thesis on "The Role of Copper in Murine Lymphocyte Blastogenesis in vitro"
1985	Exeter College, University of Oxford <b>M.A. (status)</b>	



### **Previous Appointments**

1971-72	National Science Foundation Undergraduate Research Fellowship. Madison Wisconsin. Supervisor Dr. W. H. Orme-Johnson, Institute for Enzyme Research.
1973-74	Clinical Oncology Research Honours Fellowship, Supervisor, Dr. R. Bleier, Department of Neurophysiology, University of Wisconsin Medical School.
1976	Clinical Preceptorship, University Hospital, Madison Wisconsin, and Woodruff Memorial Hospital, Woodruff Wisconsin.
1976-80	Teaching Assistant, Department of Biochemistry, University of Wisconsin - Madison.
1975-76	National Institute of Health Medical Scientist Predoctoral Fellowship. Supervisor, Dr. W.H. Orme-Johnson. Department of Biochemistry, University of Wisconsin - Madison.
1976-79	National Institute of Health Medical Scientist Postdoctoral Fellowship, Supervisor, Dr. W.H. Orme-Johnson, Department of Biochemistry, University of Wisconsin - Madison and Department of Chemistry Massachusetts Institute of Technology, Cambridge, Massachusetts.
1980	North Atlantic Treaty Organisation International Fellowship (USA) with Dr. R.A. Dwek working on "A Magnetic Resonance Approach to the Structural Basis of Antibody Specificity, Diversity and Effect" Department of Biochemistry, University of Oxford, Oxford, England.
1980	Medical Research Council Fellow - Recognition in Immune Response, October 1980 - April 1981
1980-82	Fellow of Institute of Medicine and Mathematics (USA). Department of Biochemistry, University of Oxford, Oxford, England.
1982	Wellcome Research Fellow - "Immunoglobulins as Glycoproteins" Department of Biochemistry, Oxford.
1982-83	Fellow of Institute of Medicine and Mathematics (USA). Department of Biochemistry, University of Oxford, Oxford, England.
1983-84	Lecturer, Biochemistry, Exeter College, Oxford.
1983-88	Monsanto Senior Research Fellow, Department of Biochemistry, University of Oxford, England.
1988-91	Director, Clinical and Research, Oxford Glycobiology Unit
1991-93	Senior Research Fellow, Oxford Glycobiology Institute.
1993-94	Senior Clinical Lecture, Dept. of Molecular Pathology, University College London Medical School.
1994-	Professor of Molecular Medicine and Head-Molecular Medicine Unit, University College London Medical School. Senior

Postgraduate Tutor and Head of Admissions Dept. of Molecular Pathology.

### **Major Research Area(s)**

Rheumatology/Immunology/Diabetes/Asthma/Glycobiology/Growthfactors/Cell signalling

### **Major Research Achievements**

#### **Rheumatoid Arthritis.**

Association of adult rheumatoid arthritis with changes in the glycosylation pattern of antibodies. \*Correlation of glycosylation changes of antibodies with clinical score in juvenile arthritis. \* Changes in antibody glycosylation during pregnancy and the relevance to remission of arthritis. \*Changes with disease in the glycosylation of antibodies restricted to Crohn's disease, tuberculosis and rheumatoid arthritis. \* Changes in glycosylation of antibodies with age. \* First description of oligosaccharides in the Fab fragment of antibodies.

#### **Glycobiology.**

Description of basic concepts and principles; definition of glycoforms and glycotypes.

#### **Oligosaccharide Sequencing technology.**

First rational approach to automated micro sequencing. \*Establishment of enzyme bank of oligosaccharide sequencing.\*Description of dry phase enzyme method. \*Synthesis of methylation standards for GC-mass spectroscopy. \* Use of hydrazine to release oligosaccharides intact and quantitatively. \* Optimization of reduction conditions.

#### **Characteristics of N-glycosylation.**

Description of glycoforms and demonstration of site specific and cell specific N-glycosylation in Thy-1 and tissue plasminogen activator (t-PA). \* Relationship of t-PA glycoforms to biological activity.

#### **Oligosaccharide Structure from NMR.**

The first solution conformation of an N-linked oligosaccharide and the first description of secondary structure in N-linked oligosaccharides.

#### **Lipid Anchors.**

First description of the structures of glycan lipid anchors. \*Variable surface glycoprotein Trypanosoma brucei \* Lipophosphoglycan (LPG) from Leishmania. \*Thy-1 from rat brain.

**Parasitology.**

Characterisation of glycosylation patterns. \* GP63, major surface glycoprotein from *Leishmania mexicana amazonensis*, \* Major carbohydrate fragment of *Leishmania donovani* lipophosphoglycan. *Trypanosoma brucei*-type-1 VSG.

**Pregnancy.**

Identification of an immunosuppressive agent from placental glycocalyx. Description of glycogen accumulation in pre-eclampsia.

**Anti-viral Agents.**

Demonstration that amino sugars are potential anti HIV agents.

**Neural cell-adhesion molecules.**

First evidence for expression of O-linked glycosylation.

**Plants.**

First characterisation of a fucose/xylose substituted oligosaccharide in plant lectins.

**Oligosaccharide derivitization.**

First successful application of aqueous chemistry for preparing glycol derivatives of oligosaccharides.

**Diabetes.**

First partial structures of the insulin second messenger. Description of the pathogenesis of syndrome X in diabetes. Discovery of manganese and zinc co-factors as insulin second messengers.

**Pre-eclampsia.**

Description of altered release of insulin second messengers on placenta leading to glycogen accumulation.

**Hypertension.**

Description of manganese co-factor which bind nitric oxide.

**Tuberculosis.**

Description of phosphoglycolines in mycobacteria which mimic mammalian insulin second messengers.

**Malaria.**

Description of phosphoglycolines in malaria which mimic mammalian insulin second messengers.

**Editorial Boards**

1988 - Editor, *Advances in Glycobiology*.

### **Scientific Research Groups**

Oxford Oligosaccharide Group  
Oxford Glycobiology Group  
Royal Society of Medicine

### **Industrial Boards**

Oxford GlycoSystems	1987 -1996
Lascaux Pharmaceuticals	1995 -
Rodaris Pharmaceuticals Ltd	1996 – 2001
Midatech Ltd	2000 -
Sylus Pharmaceuticals Ltd	2002 –
Vacsys Ltd	2002 -

### **Consultancies**

Monsanto Co	1984 -1992
Oxford GlycoSciences Group Plc	1987 -1991
INSMED Pharmaceuticals	1994 -1995
Mallinkrodt Medical	1995
Oxford GlycoSciences Group Plc	1996

### **Companies Founded**

Oxford GlycoSciences Plc	1987
Rodaris Pharmaceuticals Ltd	1996
Lascaux Pharmaceuticals Ltd	1996
Midatech Ltd	2000
Sylus Pharmaceuticals	2002
Vacsys Ltd	2002

**Thomas Rademacher:**  
**Research Publications**  
**(1980-Present)**

1. **The C1q Receptor Site on Immunoglobulin G.** D.R. Burton, J. Boyd, A.D. Brampton, S.B. Easterbrook-Smith, E.J. Emanuel, J. Novotny, T.W. Rademacher, M.R. von Schravendijk, M.J.E. Sternberg and R.A. Dwek (1980) *Nature* 288, 338-344.
2. **Solution conformation of the biantennary N-linked oligosaccharide of human serotransferrin using  $^1\text{H}$  NMR nuclear overhauser effect measurements.** S.W. Homans, R.A. Dwek, D.L. Fernandes and T.W. Rademacher (1982) *FEBS Lett.* 150, 503-506.
3. **Structural, functional and conformational analysis of immunoglobulin G-derived asparagine-linked oligosaccharides.** T.W. Rademacher and R.A. Dwek (1983) *Progress in Immunology*, vol. V, 95-112.
4. **Structural and conformational analysis of immunoglobulin-derived N-linked oligosaccharides.** T.W. Rademacher, S.W. Homans, D.L. Fernandes, R.A. Dwek, T. Mizuochi, T. Taniguchi and A. Kobata (1983) *Biochem. Society Transactions* 11, 132-134.
5. **Solution conformation of biantennary complex type oligosaccharides: Determination of major conformers about the glycosidic linkages.** S.W. Homans, R.A. Dwek, D.L. Fernandes and T.W. Rademacher (1983) *FEBS Lett.* 164, 231-235.
6. **The use of two-dimensional correlated spectroscopy to obtain new assignments in the high-resolution  $^1\text{H}$  nuclear magnetic resonance spectrum of the biantennary complex oligosaccharide isolated from human serum transferrin by hydrazinolysis.** S.W. Homans, R.A. Dwek, D.L. Fernandes and T.W. Rademacher (1983) *Biochimica et Biophysica Acta*, 760, 256-261.
7. **The analysis of coupling networks in a complex oligosaccharide mixture derived from the Fc region of rabbit immunoglobulin G using  $^1\text{H}$ - $^1\text{H}$  correlated NMR spectroscopy combined with double quantum NMR spectroscopy.** S.W. Homans, R.A. Dwek, D.L. Fernandes and T.W. Rademacher (1984) *Biochimica et Biophysica Acta*, 798, 78-83.
8. **Structure-function relationship in immunoglobulins.** R.A. Dwek, B.J. Sutton, S.J. Perkins and T.W. Rademacher (1984) in *Molecular Variants of Protein - Biosynthesis and Clinical Relevance* - ed. P.N. Campbell and C. Phelps. *Biochem. Soc. Symposium* 49, 123-136.

9. **Multiple-step relayed correlation spectroscopy: Sequential resonance assignments in oligosaccharides.** S.W. Homans, R.A. Dwek, D.L. Fernandes and T.W. Rademacher (1984) *Proc. Natl. Acad. Sci.* **81**, 6286-6289.
10. **Immunoglobulin G as a glycoprotein.** T.W. Rademacher, S.W. Homans, R.B. Parekh and R.A. Dwek (1985) *Genes and Proteins in Immunity - in honour of Professor R.R. Porter - Biochem. Soc. Symp. No: 51*, 131-149 (ed. J. Jay, M.A. Kerr, A.F. Williams and K.B.M. Reid).
11. **Effector functions of a monoclonal aglycosylated Mouse IgG2a: Binding and activation of complement component C1 and interaction with human monocyte Fc receptor.** R.J. Leatherbarrow, T.W. Rademacher, R.A. Dwek, J.M. Woof, A. Clark, D.R. Burton, N. Richardson and A. Feinstein (1985) *Molecular Immunology*, **22**, 407-415.
12. **Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG.** R.B. Parekh, R.A. Dwek, B.J. Sutton, D.L. Fernandes, A. Leung, D. Stanworth, T.W. Rademacher, T. Mizuochi, T. Taniguchi, K. Matsuta, F. Takeuchi, Y. Nagano, T. Miyamoto and A. Kobata (1985) *Nature* **316**, 452-457.
13. **Structures of the sugar chains of rabbit immunoglobulin G: Occurrence of asparagine-linked sugar chains in Fab fragment.** T. Taniguchi, T. Mizuochi, M. Beale, R.A. Dwek, T.W. Rademacher and A. Kobata (1985) *Biochemistry*, **24**, 5551-5557.
14. **Conformational transitions in N-linked oligosaccharides.** S.W. Homans, R.A. Dwek, J. Boyd, M. Mahmoudian, W.G. Richards and T.W. Rademacher (1986) *Biochemistry* **25**, 6342-6350.
15. **Synthesis of 2-Acetamido-1,5-imino-1,2,5-trideoxy-D-mannitol and of 2-Acetamido-1,5-imino-1,2,5-trideoxy-D-glucitol, a potent and specific inhibitor of a number of  $\beta$ -N-Acetylglucosaminidases.** G.W.J. Fleet, P.W. Smith, R.J. Nash, L.E. Fellows, R.B. Parekh and T.W. Rademacher. (1986) *Chemistry Letters* 1051-1054.
16. **A method for the rapid assignment of  $^1\text{H}$  NMR spectra of oligosaccharides using homonuclear Hartmann-Hahn spectroscopy.** S.W. Homans, R.A. Dwek, J. Boyd, N. Soffe and T.W. Rademacher (1987) *Proc. Natl. Acad. Sci. USA* **84**, 1202-1205.
17. **Tissue-specific N-glycosylation, site-specific oligosaccharide patterns and lentil lectin recognition of rat Thy-1.** R.B. Parekh, A.G.C. Tse, R.A. Dwek, A.F. Williams and T.W. Rademacher (1987) *EMBO J* **6**, 1233-1244.
18. **The  $\beta$ 2-D-xylose and  $\alpha$ 3-L-fucose substituted N-linked oligosaccharides from *Erythrina cristagalli* lectin. Isolation, characterization and comparison with other legume lectins.** D. Ashford, R.A. Dwek, J.K. Welply, S. Amatayakul, S.W. Homans, H.

- Lis, G.N. Taylor, N. Sharon and T.W. Rademacher (1987) *Eur. J. Biochem.* 166, 311-320.
19. **Structural studies on the glycopospholipid membrane anchor of *Trypanosoma brucei* variant surface glycoprotein.** M.A.J. Ferguson, R.A. Dwek, S.W. Homans and T.W. Rademacher (1987). In: *NATO/ASI. vol. H11 Host-Parasite Cellular and Molecular Interaction in Protozoal Infections*, p.p. 19-28 (eds. K-P. Chang and D. Snary)
  20. **Oligosaccharide conformation.** C.J. Edge, S.W. Homans, R.A. Dwek and T.W. Rademacher (1987) *Fourth European Seminar and Exhibition on Computer-Aided Molecular Design*, 1987, IBC Technical Services Ltd.
  21. **Identification of phosphorylated 3-deoxy-manno-octulosonic Acid as a component of *Haemophilus influenzae* lipopolysaccharide.** S.E. Zamze, M.A.J. Ferguson, E.R. Moxon, R.A. Dwek and T.W. Rademacher (1987) *Biochem. J.* 245, 583-587.
  22. **Tertiary structure in N-linked oligosaccharides.** S.W. Homans, R.A. Dwek and T.W. Rademacher (1987) *Biochemistry* 26, 6553-6560.
  23. **Structure and dynamics in oligomannose-type oligosaccharides.** S.W. Homans, A. Pastore, R.A. Dwek and T.W. Rademacher (1987) *Biochemistry* 26, 6649-6655.
  24. **Solution conformations of N-linked oligosaccharides.** S.W. Homans, R.A. Dwek and T.W. Rademacher (1987) *Biochemistry* 26, 6571-6578.
  25. **Structure of the major carbohydrate fragment of the *Leishmania donovani* lipophosphoglycan.** S.J. Turco, S.R. Hull, P.A. Orlandi, Jr., S.D. Shepherd, S.W. Homans, R.A. Dwek and T.W. Rademacher (1987) *Biochemistry* 26, 6233-6238.
  26. **The glycosylphosphatidylinositol membrane anchor of *Trypanosoma brucei* variant surface glycoprotein.** M.A.J. Ferguson, S.W. Homans, R.A. Dwek and T.W. Rademacher (1988) *Biochemical Transactions* 16, 265-268.
  27. **Glycobiology.** T.W. Rademacher, R.B. Parekh and R.A. Dwek (1988) *Ann. Rev. Biochem.* 57, 785-838.
  28. **Rheumatoid arthritis as a glycosylation disorder.** R.B. Parekh, R.A. Dwek and T.W. Rademacher (1988) *British Journal of Rheumatology* 27 (suppl 11) 162-169.
  29. **The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis.** T.W. Rademacher, R.B. Parekh, R.A. Dwek, D. Isenberg, G. Rook, J.S. Axford and I. Roitt. (1988). *Springer Seminars in Immunopathology* 10, 231-249.
  30. **Changes in carbohydrate structure of IgG in rheumatoid arthritis.** I.M. Roitt, R.A. Dwek, R.B. Parekh, T.W. Rademacher, A. Alavi, J.S. Axford, K.B. Bodman, A. Bond, A. Cooke,

- F.C. Hay, D.A. Isenberg, P.M. Lydyard, L. MacKenzie, G. Rook, M. Smith, N. Sumar, (1988). *Recenti Progressi in Medicine*, 79, 314-317.
31. **The Thy-1 glycoprotein: a three-dimensional model.** S.J. Perkins, A.F. Williams, T.W. Rademacher and R.A. Dwek. (1988) *TIBS* 13, 302-303.
  32. **The role of oligosaccharides in modifying protein function.** T.W. Rademacher and R.A. Dwek. (1988). *CIBA Foundation Symposia*, p.p. 241-256.
  33. **Age-related galactosylation of N-linked oligosaccharides of human serum IgG.** R.B. Parekh, I.M. Roitt, D.A. Isenberg, R.A. Dwek, and T.W. Rademacher (1988) *J. Exp. Med.* 167, 1731-1736.
  34. **Galactosylation of IgG associated oligosaccharides: Reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity.** R.B. Parekh, D.A. Isenberg, B.M. Ansell, I.M. Roitt, R.A. Dwek and T.W. Rademacher (1988) *Lancet* i, 966-969.
  35. **Glycosyl-phosphatidylinositol moiety that anchors *Trypanosoma brucei* variant surface glycoprotein to the membrane.** M.A. Ferguson, S.W. Homans, R.A. Dwek and T.W. Rademacher (1988) *Science* 239, 753-759.
  36. **A Monoclonal Antibody raised by immunising mice with group A streptococci binds to agalactosyl IgG from rheumatoid arthritis.** G.A.W. Rook, J. Steele, and T.W. Rademacher. (1988) *Ann. Rheum. Dis.* 47, 247-250.
  37. **Identification of a monoclonal antibody to abscission tissue that recognises xylose/fucose-containing N-linked oligosaccharides from higher plants.** M.T. McManus, J. McKeating, D.S. Secher, D.J. Osborne, D. Ashford, R.A. Dwek and T.W. Rademacher (1988) *Planta* 175, 506-512.
  38. **δ-Lactams: Synthesis from D-glucose, and preliminary evaluation as a fucosidase inhibitor of L-Fuconic-δ-lactam.** G.W. Fleet, N.G. Ramsden, R.A. Dwek, T.W. Rademacher, L.E. Fellows, R.J. Nash, D.St.C. Green and B. Winchester (1988) *J. Chem. Soc. Chem. Commun.* 1779, 482-485.
  39. **Complete structure of the glycosylphosphatidylinositol membrane anchor of rat brain Thy-1 glycoprotein.** S.W. Homans, M.A.J. Ferguson, R.A. Dwek, T.W. Rademacher, R. Anand and A.F. Williams (1988) *Nature* 333, 269-272.
  40. **Characterisation of the cross-reacting determinant (CRD) of the glycosyl-phosphatidylinositol membrane anchor of *Trypanosoma brucei* variant surface glycoprotein.** S.E. Zamze, M.A.J. Ferguson, R. Collins, R.A. Dwek and T.W. Rademacher (1988) *Eur. J. Biochem* 176, 527-534.



41. **Galactose residues in chronic inflammatory disease.** J.S. Axford, L. Mackenzie, P.M. Lydyard, F.C. Hay, D.A. Isenberg, I.M. Roitt, G. Rook, T.W. Rademacher, R.B. Parekh and R.A. Dwek. (1988) *Lancet* 418.
42. **The role of antigen in autoimmune responses with special reference to changes in carbohydrate structure of IgG in rheumatoid arthritis.** Roitt, I.M., Dwek, R.A., Parekh, R.B., Rademacher, T.W., Alavi, A., Axford, J.S., Bodman, K.B., Bond, A., Cooke, A., Hay, F.C., Isenberg, D.A., Lydyard, P.M., Mackenzie, L., Rook, G., Smith, M. and Sumar, N. (1988) *J. Autoimmunity* 1, 499-506.
43. **Inhibition of HIV replication by amino-sugar derivatives.** G.W.J. Fleet, A. Karpas, R.A. Dwek, L.E. Fellows, A.S. Tyms, S. Petursson, S.K. Namgoong, N.G. Ramsden, P.W. Smith, J.C. Son, F. Wilson, D.R. Witty, G.S. Jacob and T.W. Rademacher (1988) *FEBS Lett.* 237, 128-132.

44. **Aminosugar derivatives as potential anti-human immunodeficiency virus agents.** A. Karpas, G.W.J. Fleet, R.A. Dwek, S. Petursson, S.K. Namgoong, N.G. Ramsden, G.S. Jacob and T.W. Rademacher (1988) *Proc. Natl. Acad. Sci.* 85, 9229-9233.
45. **N-glycosylation and the production of recombinant glycoproteins.** R.B. Parekh, R.A. Dwek, C.J. Edge, T.W. Rademacher. (1989). *Trends in Biotechnology* 7, 117-122.
46. **A comparative analysis of disease-associated changes in the galactosylation of serum IgG.** R. Parekh, D. Isenberg, G. Rook, I. Roitt, R.A. Dwek, T.W. Rademacher (1989) *J. of Autoimmunity* 2, 101-114.
47. **Solution structure of the glycosylphosphatidylinositol membrane anchor glycan of *Trypanosoma brucei* variant surface glycoprotein.** S.W. Homans, C.J. Edge, M.A.J. Ferguson, R.A. Dwek and T.W. Rademacher (1989) *Biochemistry* 28, 2881-2887.
48. **Tissue specific O-linked glycosylation of the neural cell adhesion molecule (N-CAM).** Walsh, F.S., Parekh, R.B., Moore, S.E., Dickson, G., Barton C.H., Gower, H.J., Dwek R.A. and Rademacher, T.W. (1989) *Development* 105, 803-811.
49. **Structure of the phosphosaccharide-inositol core of the *Leishmania donovani* lipophosphoglycan.** Turco, S.J., Orlandi, Jr., P.A., Homans, S.W., Ferguson, M.A.J., Dwek, R.A., Rademacher, T.W. (1989) *J. Biol. Chem.* 264, 6711-6715.
50. **Structure function studies on Leishmania surface membrane protein.** R.W. Olafson, R.A. Dwek, T.W. Rademacher, K.-P. Chang and M.A.J. Ferguson (1989) in 'Leishmaniasis: Current Status and New Strategies for Control' - ed. D.T. Hart. Plenum Press, New York, 1989.
51. **Cell-type-specific and site-specific N-glycosylation of type I and type II human tissue plasminogen activator.** R.B. Parekh, R.A. Dwek, J.R. Thomas, T.W. Rademacher, G. Opdenakker., A.J. Wittwer, S.C. Howard., R. Nelson, N.R. Siegel, M.G. Jennings, N.K. Harakas and J. Feder. (1989) *Biochemistry* 28, 7644-7662.
52. **Effects of N-glycosylation on *in vitro* activity of Bowes melanoma and human colon fibroblast-derived tissue plasminogen activator.** A.J. Wittwer, S.C. Howard, L.Carr, N.K. Harakas, J. Feder, R.B. Parekh, P.M. Rudd, R.A. Dwek and T.W. Rademacher (1989) *Biochemistry* 28, 7662-7669.
53. **N-glycosylation and *in vitro* enzymatic activity of human recombinant tissue plasminogen activator expressed in chinese hamster ovary cells and a murine cell line.** R.B. Parekh, R.A. Dwek, P.M. Rudd, J.R. Thomas, T.W. Rademacher, T. Warren, T.C. Wun, B. Hebert, B. Reitz, M. Palmier, T. Ramabhadran and D.C. Tiemeier. (1989) *Biochemistry* - 28, 7670-7679.

54. **O-Linked oligosaccharides from human serum immunoglobulin A1.** Field, M.C., Dwek, R.A. and Rademacher, T.W. (1989) *Biochem. Soc. Trans.* 17, 1034-1035.
55. **A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodosum leprosum.** Filley, E., Andreoli, A., Steele, J., Waters, M., Wagner, D., Nelson, D., Tung, K., Rademacher, T.W., Dwek, R.A., Rook G.A.W. (1989) *Clin. & Exp. Immunol.* 76, 343-7.
56. **Structure, biosynthesis and function of glycosyl phosphatidylinositols.** J.R. Thomas, R.A. Dwek and T.W. Rademacher. (1990). *Perspectives in Biochemistry* 29, 5413-5422.
57. **The significance of changes in IgG carbohydrate in rheumatoid arthritis and tuberculosis.** I.M. Roitt, R.A. Dwek, R.B. Parekh, T.W. Rademacher, C. Warren, A. Alavi, J.S. Axford, K. Bodman, A. Bond, B. Colaco, A. Cooke, P. Delves, F.C. Hay, D.A. Isenberg, P.M. Lydyard, L. MacKenzie, G. Rook, M. Smith, N. Sumar and G. Tsoulfa. (1990) *Molecular Aspects of Immune Response and Infectious Diseases*, Ed. H. Kiyona, E. Jirillo and C. DeSimone. Raven Press, New York.
58. **Extracting subspectra from overlapping regions. DOUBLE TOCSY.** Bazzo, R., Edge, C.J., Dwek, R.A. and Rademacher, T.W. (1990) *J. Mag. Res.* 86, 199-203.
59. **Characterisation of the asparagine-linked oligosaccharides from *Trypanosoma brucei* type I variant surface glycoproteins.** Zamze, S.E., Wooten, E.W., Ashford, D.A., Ferguson, M.A.J., Dwek, R.A., Rademacher, T.W. (1990) *Eur. J. Biochem.* 187, 657-663.
60. **500-picosecond molecular dynamics in water of the Man $\alpha$ 1'2Man $\alpha$  glycosidic linkage present in asn-linked oligomannose-type structures on glycoproteins.** Edge, C.J., Singh, U.C., Bazzo, R., Taylor, G.L., Dwek, R.A. and Rademacher, T.W. (1990) *Biochemistry* 29, 1971-1974.
61. **Primary sequence dependence of conformation in oligomannose oligosaccharides.** Wooten, E.W., Bazzo, R., Edge, C.J., Zamze, S., Dwek, R.A. and Rademacher, T.W. (1990) *J. Eur. Biophysics* 18, 139-148.
62. **Glycolipid precursors for the membrane anchor of *Trypanosoma brucei* variant surface glycoproteins: I. Can structure of the phosphatidylinositol-specific phospholipase C sensitive and resistant glycolipids.** Mayor, S., Menon, A.K., Cross, G.A.M., Ferguson, M.A.J., Dwek, R.A. and Rademacher, T.W. (1990) *J. Biol. Chem.* 265, 6164-6173.
63. **Neither Agalacostyl IgG, nor Antibodies to Heat Shock Proteins are raised in Acute Rheumatic Fever.** G.M. Bahr, A.M. Yousof, H.A.M. Majeed, K. Behbehani, K., M.

- Lubani., R.B. Parekh, R.A. Dwek, T.W. Rademacher, D.B. Young, A. Mehlert, J. Steele, and G.A.W. (1990) *Ann. Rheum. Dis.* 49, 383-386.
64. **Agalactosyl IgG in inflammatory bowel disease: Correlation with C-reactive protein.** Dube, R., Rook, G.A.W., Steele, J., Brealey, R., Dwek, R.A., Rademacher, T.W., Lennard-Jones, J. (1990) *Gut* 31, 431-434.
65. **Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering.** Perkins, S.J., Smith, K.F., Amatayakul, S., Ashford, D., Rademacher, T.W., Dwek, R.A., Lachmann, P.J., Harrison, R.A. (1990) *J. Mol. Biol.* 214, 751-763.
66. **Analysis of glycosylation changes of IgG using lectins.** Sumar, N., Bodman, K., Rademacher, T.W., Dwek, R.A., Williams, P., Parekh, R.B., Edge, J., Rook, G.A.W., Isenberg, D.A., Hay, F.C. & Roitt, I.M. (1990) *J. Immunol. Meth.* 131, 1 127-136.
67. **Structures of the N-linked oligosaccharides of Gp63, the major surface glycoprotein, from *Leishmania mexicana amazonensis*.** Olafson, R.W., Thomas, J.E., Ferguson, M.A.J., Dwek, R.A., Chaudhuri, M., Chang, K.P. and Rademacher, T.W. (1990) *J. Biol. Chem.* 265, 12240-12247.
68. **Uncertainties in structural determinations of oligosaccharide conformation using measurements of nuclear Overhauser effects.** Wooten, E.W., Edge, C.J., Bazzo, R., Dwek, R.A. and Rademacher, T.W. (1990) *Carbohydrate Research* 203: 1 13-17.
69. **Full simulation of ROESY, including the Hartmann-Hahn effects.** Bazzo, R., Edge, C.J., Wormald, M.R., Rademacher, T.W. and Dwek, R.A. (1990) *Chem. Phys. Letts.* 174, 313-319.
70. **The isolation by ligand-affinity chromatography of a novel form of  $\alpha$ -L-fucosidase from almond.** Scudder, P., Neville, D.C.A., Butters, T.D., Fleet, G.W.J., Dwek, R.A., Rademacher, T.W. and Jacobs, G.S. (1990) *J. Biol. Chem.* 265 16472-16477.
71. **Dropping anchor with the Lipophosphoglycans.** T.W. Rademacher, C.J. Edge, and R.A. Dwek (1991). *Current Biology* 1,41-42.
72. **Diversification of the IgG molecule by oligosaccharides.** P.M. Rudd, R.J. Leatherbarrow, T.W. Rademacher and R.A. Dwek. (1991) *Mol. Immunol.* 28, 1369-1378.
73. **Network theory of glycosylation - etiologic and pathogenic implications of changes in IgG glycoform levels in autoimmunity.** T.W. Rademacher (1991). *Seminars in Cell Biology* 2, 327-337.

USSN 09/868,879  
Schofield et al.  
pg.21

74. **Syncytiotrophoblast membrane glycoprotein components block lymphocyte proliferation by interfering with an early event in their activation.** P.D. Arkwright, C.W.G. Redman (1991) *Cellular and Molecular Biology of the Materno-Fetal Relationship* (Eds: G. Chaouat & J Mowbray) Vol. 212, pp. 227-235.

75. **The role of oil and agalactosyl IgG in the induction of arthritis in rodent models.** Rook, G., Thompson, S., Buckley, M., Elson, C., Brealey, R., Lambert, C., Whyte, T and Rademacher, T. (1991) *Eur. J. Immunol.* 21, 1027-1032.
76. **The glycosylation of glycoprotein lectins: Intra- and inter-genus variation in N-linked oligosaccharide expression.** Ashford, D.A., Dwek, R.A., Rademacher, T.W., Lis, H. and Sharon, N. (1991) *Carbohydrate Research* 213, 215-227.
77. **Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy.** Rook, G.A.W., Steele, J., Brealey, R., Whyte, A., Isenberg, D., Sumar, N., Nelson, J.L., Bodman, K.B., Young, A., Roitt, I.M., Williams, P., Scragg, I., Edge, C.J., Arkwright, P.D., Ashford, D., Wormald, M., Rudd, P., Redman, C.W.G., Dwek, R.A. & Rademacher, T.W. (1991) *J. Autoimmunity* 4, 779-794.
78. **Characterisation of oligosaccharides from *Drosophila melanogaster* glycoproteins.** Williams, P.J., Wormald, M.R., Dwek, R.A., Rademacher, T.W., Parker, G.F. and Roberts, D.R. (1991) *Biochimica et Biophysica Acta* 1075, 146-153.
79. **Cell surface oligosaccharides on *Dictyostelium* during development.** Amatayakul-Chantler, S., Ferguson, M.A.J., Dwek, R.A., Rademacher, T.W., Parekh, R.B., Crandall, I.E. and Newell, P.C. (1991) *J. Cell Science.* 99, 485-495.
80. **Structural characterization of the asparagine-linked oligosaccharides from *Trypanosoma brucei* type II and type III variant surface glycoproteins.** Zamze, S.E., Ashford, D.A. Wooten, E.W., Rademacher, T.W. and Dwek, R.A. (1991) *J. Biol. Chem.* 266, 20244-20261.
81. **Glycoprotein glycosylation and the immuno-suppressive effects of human pregnancy serum.** Arkwright, P., Rademacher, T.W., Marshall, J., Dwek, R.A. and Redman, C. (1991) *J. Reproductive Immunology* 21, 97-102.
82. **Syncytiotrophoblast membrane protein glycosylation patterns in normal human pregnancy and changes with gestational age and parturition.** Arkwright, P.D., Redman, C.W.G., Williams, P.J., Dwek, R.A. and Rademacher, T.W. (1991) *Placenta* 12, 637-651.
83. **Abnormalities in the Glycosylation of IgG in Spouses of Patients with Rheumatoid Arthritis. A Family Study.** Sumar, N., Colaco, C.B., Bodman, K.B., Parekh, R.B., Williams, P., Dwek, R.A., Rademacher, T.W., Isenberg, A., Hay, F.C. and Roitt, I.M. (1991) *J. Autoimmunity* 4, 907.
84. **1-N-Glycyl B-Oligosaccharides using arrays of enzymes.** Manger Id, Rademacher T, Dwek R. (1992) *Biochem*: 31:44 – 10724 - 10732

85. **Fast sequencing of oligosaccharides using arrays of enzymes.** Edge, C, Parkh R, Rademacher T, Wormold, Dwek R. (1992) *Nature* 358: 693 - 694
86. **Therapeutic challenges. Does glycobiology have a role?** T.W. Rademacher. (1992) *Trends in Biotechnology* 10, 227-230.
87. **Glycobiology.** T.W. Rademacher and R.A. Dwek (1992). Fundamentals of Medical Cell Biology, Vol. 3A. *Chemistry of the Living Cell*, 257-312. (JAI Press Inc.)
88. **Glycosylation of interleukin-6 purified from human blood mononuclear cells.** Parekh, R.B., Dwek, R.A. Rademacher, T.W., Opdenakker, G., and Van Damme, J. (1992) *Eur. J. Biochem.* 203, 135-141.
89. **Abnormal Glycosylation of the Syncytiotrophoblast Membrane Proteins in the Pre-eclamptic Placenta.** P.D. Arkwright, T.W. Rademacher, R.A. Dwek and C.W.G. Redman. (1992). *J.Clin. Invest.* 91, 2744-2753.
90. **Detection of Multisulphated N-Linked Glycans in the L2/HNK-1 Carbohydrate Epitope Expressing Neural Adhesion Molecule Po.** Field, M.C., Wing, D.R., Dwek, R.A., Rademacher, T.W., Schmitz, B., Bollensen, E. and Schachner, M. (1992) *J. of Neurochem* 58, 993-1000.
91. **The use of 'large scale' hydrazinolysis in the preparation of N-linked oligosaccharide libraries: application to brain tissue.** D.R. Wing, T.W. Rademacher, M.C. Field, R.A. Dwek. (1992) *Glyconjugate J.* 9, 293-301.
92. **Fast Sequencing of Oligosaccharides: The Reagent Array Analysis Method.** Edge, C.J., Rademacher, T.W., Wormald, M.R., Parekh, R.B., Butters, T.D., Wing, D.R. and Dwek, R.A. (1992) - *Proc. Natl. Acad. Sci. USA* 89, 6338-6342.
93. **Site-specific glycosylation of recombinant rat and human soluble CD4 variants expressed in chinese hamster ovary cells.** Ashford D.A., Alafi C.D., Gamble V.M., Mackay D.J.G., Rademacher T.W., Williams P.J., Dwek R.A., Barclay A.N., Davis S.J., Somoza C., Ward H.A. and Williams A.F. (1992) *J. Biol. Chem.*, 268, 3260-3267.
94. **Synthesis of 1-N-glycyl- $\beta$ -oligosaccharide derivatives: reactivity of Lens culinaris lectin with a streptavidin pseudoglycoprotein and immobilized neoglycolipid.** Manger I.D., Rademacher T.W. and Dwek R.A. (1992) *Biochemistry*, 31, 10733-10740.
95. **Comparative glycosylation in neural adhesion molecules.** Wing, D.R., Rademacher, T.W., Schmitz, B., Schachner, M. and Dwek, R.A. (1992) *Biochem. Soc. Transactions* 20, 386-390.

96. **Pre-eclampsia is associated with an increase in trophoblast glycogen content and glycogen synthase activity, similar to that found in hydatiform moles.** Arkwright PD, Rademacher TW, Dwek RA, Redman CW (1993) *J. Clin. Invest.* 91: 2744-2753
97. **Glycosylation of CD4 and Thy-1.** R.A. Dwek, D.A. Ashford, C.J. Edge, R.B. Parekh, T.W. Rademacher, D.R. Wing, A.N. Barclay, S.J. Davis and A. F. Williams. (1993). *Phil. Trans. R. Soc. Lond. B* 342, 43-50.
98. **Conservation and evolution of glycosylation sites on immunoglobulin-type domains.** T.W. Rademacher and I.B.H. Wilson. (1993). *Glycobiology* 3, 418
99. **Glycosylation as a factor affecting product consistency.** T.W. Rademacher. (1993). *Biologicals* 21, 103-104.
100. **Molecular characterization of limulus polyphemus C-reactive protein. I. Subunit composition.** Tennant, G.A., Butler, P.J.G., Hutton, T., Woolfitt, A.R., Harvey, D.J., Rademacher, T.W. and Pepys, M.B. (1993) *Eur. J. Biochem.* 214, 91-97.
101. **Molecular characterization of limulus polyphemus C-reactive protein. II. Asparagine-linked oligosaccharides.** Amatayakul-Chantler, S., Dwek, R.A., Tennent, G.A., Pepys, M.B. and Rademacher, T.W. (1993) *Eur. J. Biochem.* 214, 99-110.
102. **Abberant control of galactosyltransferase in peripheral B-lymphocytes and Epstein-Barr virus transformed B-lymphoblasts from rheumatoid arthritic patients.** Wilson, I.B.H., Platt, F.M., Isenberg, D.A. and Rademacher, T.W. (1993) *J. Rheumatol.* 20, 1282-1287.
103. **Comparative analysis of the N-glycans of rat, mouse and human Thy-1. Site-specific oligosaccharide patterns of neural Thy-1, a member of the immunoglobulin superfamily.** Williams A.F., Parekh R.B., Wing D.R., Willis A.C., Barclay A.N., Dalchau R., Fabre J.W., Dwek R.A. and Rademacher T.W. (1993) *Glycobiology* 3, 339-348.
104. **Synthetic glycosylation of peptides using unprotected saccharide  $\beta$ -glycosylamines.** Wong S., Guile G., Rademacher T.W. and Dwek R.A. (1993) *Glycoconjugate J.* 10, 227-234.
105. **Analysis of carbohydrate-protein interactions with synthetic N-linked neoglycoconjugate probes.** Wong S., Guile G., Manger I., Rademacher T.W. and Dwek R.A. (1993) *Biochem J.* 296, 817-825.
106. **Inhibitors of HIV glycosylation enzymes.** T.W. Rademacher (1994). In: *Design of Enzyme Inhibitors as Drugs Vol. II* (ed. M. Sandler, H.J. Smith) Oxford University Press.



107. **The agalactosyl glycoform of IgG autoantibodies are pathogenic in collagen II arthritis in mice.** Rademacher T.W., Williams P. and Dwek R.A. (1994) *Proc. Natl. Acad. Sci.* 91, 6123-6127.
108. **Human Serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.** Pepys Mb, Rademacher TW, Amatayakul-Cantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, Hutton T, Dwek RA. (1994) *Proc. Natl. Acad Sci USA*, 91: 5602 - 5606
109. **Inositolphosphoglycan second messengers.** T.W. Rademacher, H. Caro, S. Kunjara, D.Y. Wang, A.L. Greenbaum and P. McLean. (1994). *Braz. J. Med. Bio. Res.* 27, 327-341.
110. **Monitoring and control of glycosylation.** T.W. Rademacher. (1994). in *Animal Cell Biotechnology Vol. 6*, 5-22. (ed. R.E. Spier and J.B. Griffiths Academic Press).
111. **Glycobiology of serum amyloid P component, a universal, homogeneous and invariant constituent of amyloid deposits.** Pepys M.B., Rademacher T.W., Amatayakul-Chantler S., Williams P., Noble G.E., Hutchinson W.L., Hawkins P.N., Nelson S.R., Gallimore J.R., Herbert J., Hutton T. and Dwek R.A. (1994) *Proc. Natl. Acad. Sci.* 91, 5602-5606.
112. **Structural analysis of the N-glycans from normal human IgA1: comparison of normal human serum immunoglobulin A1 with that isolated from patients with rheumatoid arthritis.** Field M.C., Amatayakul-Chantler S., Rademacher T.W., Rudd P.M. and Dwek R.A. (1994) *Biochem J.* 299, 261-275.
113. **Suppression of allogeneic reactivity in vitro by the syncytiotrophoblast membrane glycocalyx of the human term placenta is carbohydrate dependent.** Arkwright P.D., Rademacher T.W., Boutignon F., Dwek R.A. and Redman C.W.G. (1994) *Glycobiology* 4,39-47.
114. **Glycobiology of serum amyloid P component, a universal, homogeneous and invariant constituent of amyloid deposits.** Pepys M.B., Rademacher T.W., Amatayakul-Chantler S., Williams P., Noble G.E., Hutchinson W.L., Hawkins P.N., Nelson S.R., Gallimore J.R., Herbert J., Hutton T. and Dwek R.A. (1994) *Proc. Natl. Acad. Sci.* 91, 5602-5606.
115. **Early agalactosylation of IgG is associated with a more progressive disease course in patients with Rheumatoid Arthritis: Results of a follow-up study.** D. van Zeben, G.A.W. Rook, J.M.W. Hazes, A.H. Zwinderman, Y. Zhang, S. Ghelani, T.W. Rademacher, F.C. Breedveld (1994) *Br. J. Rheumatol.* 33, 36-43.

116. **Galactosylation of human IgG monoclonal anti-D produced by EBV -transformed B lymphoblastoid cell lines is dependent on culture method and affects the Fc receptor-mediated functional activity.** Kumpel B.M., Rademacher T.W., Rook G.A.W., Williams P.J. and Wilson I.B.H. (1994) *Hum. Antibod. Hybridomas* 5,143-151
117. **Tissue specific release of inositol phosphoglycans.** S. Kunjara, H.N.Caro, McLean, P., and T.W. Rademacher. (1995) *Proc. 11th FAOBMB Symposium Bangkok, Thailand, Nov 15-18. 1994, Biopolymers and Bioproducts: Structure, Function and Applications.*
118. **Significance and molecular basis for IgG glycosylation changes in rheumatoid arthritis.** T.W. Rademacher, R.H.V. Jones and P.J. Williams. (1995). *Advances Exp. Med. Biol.* 376:193-204.
119. **Short communication: Selective placental transport of maternal IgG to the fetus.** Williams PJ, Arkwright PD, Rudd P, Scragg I, Edge CJ, Wormald Mr, Rademacher TW. (1995) *Placenta* 16: 749 - 756
120. **Immunoglobulins carry infectious non-self mimetic carbohydrate residues. Implications for the function of antibodies in health and disease.** T.W. Rademacher, R.H.V. Jones and P.J. Williams. (1996) pp 221-252. In *Abnormalities of IgG glycosylation and immunological disorders.* edited by D A Isenberg and T W Rademacher. *John Wiley and Sons,Ltd.*
121. **The defining characteristics of immunoglobulin glycosylation.** T. W. Rademacher, A. Jaques, and P.J. Williams. (1996) pp1- 44. In *Abnormalities of IgG glycosylation and immunological disorders.* edited by D A Isenberg and T W Rademacher. *John Wiley and Sons, Ltd.*
122. **Abnormalities of IgG Glycosylation and Immunological Disorders.** (1996) Edited by D A Isenberg and T.W. Rademacher. *John Wiley and Sons, Ltd. Chichester, UK.*
123. **Selective placental transport of maternal IgG to the fetus.** Williams P.J., Arkwright P.D., Scragg I.G., Edge C.J., Wormald M.R., Rudd P.M. and Rademacher T.W. (1996) *Placenta* 16:749-756.
124. **Malaria: a tumour necrosis factor inhibitor from parasitized erythrocytes.** Sheikh, N.A., Caro, H.N., Taverne, J., Playfair, J.H.L., and Rademacher, T.W., (1996) *J. Immunol.* 87:461-466.
125. **Structural similarities of malaria toxins, insulin second messengers and bacterial endotoxin.** Caro, H.N., Sheikh, N.A., Taverne, J., Playfair, J.H.L., and Rademacher, T.W., *Infection Immun.* 64:3438-3441. (1996)
126. **Analysis of murine IgG isotype galactosylation in collagen induced arthritis.** Williams, P.J., and Rademacher, T.W., *Scand. J. Immunology.* 44:381-387. (1996)

127. **Cell signalling by inositol phosphoglcans from different species.** Varela-Nieto, I., Leon, Y., Caro, H., *Comp. Biochem. Physiol.* 115: 223 – 241, (1996)
128. **Bias in murine IgG isotype immobilisation: Implications for ELISA based IgG glycoform analyses.** Jones, R.H.V., Rademacher, T.W., Williams, P.J., *J. Immunol. Meth.* 197:109-120. (1996)
129. **Reduction in the incidence and severity of collagen-induced arthritis in DBA/1 mice, using exogenous dehydroepiandrosterone.** Williams, P.J., Jones, R.H.V., and Rademacher, T.W., *Arth. Rheum.* 40:907-911. (1997)
130. **Isolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liver.** Caro, H.N., Leon, Y., Kunjara, S., Jones, D., Avila, M.A., Mato, J.M., Varela-Nieto, I., and Rademacher, T.W., *Biochem. Molec. Med.* 61, 214-228 (1997).

131. **Isolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liver.** Caro H, Kunjara S, Rademacher T, Leon D, Jones D, Avila M, Varela-Nieto I. *Biochemical and Molecular Medicine* 61: 24 – 228 (1997).
132. **Correlation between IgG anti-type II collagen levels and arthritic severity in immune arthritis.** Williams, P.J., Jones R.H.V. and Rademacher, T.W., *Autoimmunity* (1998) 27:201-207.
133. **Syncytiotrophoblast surface membrane glycoprotein components augment the effects of tumor necrosis factor through their oligosaccharide side chains.** Arkwright P, Rademacher T, Boutignon F, taverne J, Redman C, Dwek R, Rook G. *Glycobiology* (1998)
134. **Purification and Characterisation of a Complex from Placental Syncytiotrophoblast Microvillous Membranes which Inhibits the Proliferation of Human Umbilical Vein Endothelial Cells: Possible Role in Pre-eclampsia.** Kertesz, Z., Hurst, G., Ward, M, Willis, A.C., Rademacher, T.W., Linton, E.A., Sargent, I.L., and Redman, C.W. *J. Clin. Invest.* (1998)
135. **Purification and Characterisation of a complex from placental syncytiotrophoblast microvillous membranes which inhibits the proliferation of human umbilical vein endothelial cells: possible role in pre-eclampsia.** Kertesz Z, Hurst G, Ward M, Willis A, Rademacher T, Linton E, Sargent I, Redman C. *J. Clin, Invest* (1998)
136. **Recent advances in glycoconjugate analysis and glycobiology.** Rademacher T.W., *Current Opinion in Biotechnology*), 9:74-79. (1998)
137. **GPI-PLD activity in the brush border membrane of normal human term Placenta.** Deborde, S., Puan, K., Rademacher, T.W., *Placenta*, 20:A.21, (1999).
138. **Higher detection of inositolphosphoglycans (IPG) in pre-eclamptic than in normal placenta by immunohistochemical staining.** Deborde, S., Sooranna, S.R., Williams, P.J., Mato, J., Rademacher, T.W., *Placenta*, 20: A.21, (1999).
139. **Investigation of inositolphosphoglycans (IPG) activity in the brush border membrane of normal and pre-eclamptic (PE) human placenta.** Deborde, S., Kunjara, S., Rademacher, T. *Placenta*, 20: A.20, (1999).
140. **Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changes.** Kunjara, S., Wang, D., Greenbaum, A.L., McLean, P., Kurtz, A., Rademacher, T., *Molecular Genetics and Metabolism*, 68:488 – 502 (1999).

141. **Inositol phosphoglycans and signal transduction systems in pregnancy in pre-eclampsia and diabetes. Evidence for a significant regulatory role in pre-eclampsia at placental and systemic levels.** Kunjara, S., Greenbaum, A.L., Wang, D. Mclean, P., Redman, C., Rademacher, T. *Molecular Genetics and Metabolism*, 69:144 – 158, (2000).
142. **Inositol phosphoglycans and the regulation of the secretion of leptin: *in vitro* effects on leptin release from adipocytes and the relationship to obesity.** Kunjara, S., Wang, D., McLean, P., Greenbaum, A.L., Rademacher, T.W., *Molecular Genetics and Metabolism*, 70: 61 – 68 (2000).
143. **Inositol Phosphoglycan Mediators Structurally Related to Glycosyl Phosphatidylinositol Anchors: Synthesis, Structure and Biological Activity.** Manuel Martin-Lomas, Noureddine Khier, Salud Garcia, Jean-Luc Koessler, Pedro M. Nieto, Thomas W. Rademacher. *Chem. Eur. J.* 6: 3608 - 3621 (2000)
144. **Structure and expression of the human glycosylphosphatidylinositol phospholipase D1 (GPILD1) gene.** Schofield, J N, Rademacher, T W. *Biochemica et Biophysica Acta*, 189 - 194 (2000)
145. **Inositol Phosphoglycans (IPGs) derived from plasmodium yoelii mimic insulin action *in vivo*.** Elased, K, Gumaa, K, De Souza, J, Rademacher, T J. *Endo* 167: 62 (2000)
146. **The presence of insulin-specific agalactosyl autoantibodies in nonobese diabetic mice correlates with disease progression.** Malling, D., Williams, P. J., Rademacher, T.W., Lund, T. - *Clin. Exp. Immunol.* (In press, 2001)
147. **Reversal of Type II diabetes in mice by products of malarial parasites 2. Role of inositolphosphoglycans (IPGs).** Elased, K., Gumaa, K., De Souza, J., Rahmoune, H., Playfair, J., Rademacher, T.W., *Mol Gen Metab.* 3:248 – 258 (2001)
148. **Inositol phosphoglycans and insulin sensitivity of adipocytes from two strains of rats; relation to obesity.** Kunjara, S., Greenbaum, A. L., McLean, P., Rademacher, T.W. - *Diabetologia*, 44: A177 (2001)
149. **Placentally-derived prostaglandin E<sub>2</sub> acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells.** Kvirkvelia, N., Vojnovic, I., Wamer, T.D., Athie-Morales, V., Free, P., Rayment, N., Chain, B.M., Rademacher, T.W., Lund, T., Roitt, I.M., Delves, P.J., - *Clin. Exp. Immunol.* 127:263-269 (2002)
150. **Insulin reduces serum glycosylphosphatidylinositol phospholipase D**

**levels in human type I diabetic patients and streptozotocin diabetic rats.** Schofield, J.N., Hurel, S.J., Persaud, S.J., Bell, K.M., de Souza, J.B., Rademacher, T.W. - Mol. Gen. Met, 75, vol 2: 154,161 (2002)

151. **Induction of nitric oxide synthase in murine macrophages by mycobacterial inositolphosphoglycans.** Puan, K., Rademacher, T.W., Rook, G., (In Press: Journal of Leukocyte Biology: 2003)
152. **Placental GPI-PLD is of maternal origin and its GPI substrate is absent from placentae of pregnancies associated with pre-eclampsia.** Deborde, S., Schofield, J.N., Rademacher, T.W. Journal of reproductive immunology 59: 277 – 294 (2003)
153. **Possible involvement of inositol phosphoglycan- P in human parturition.** Paine, M.A., Rodeck, C.H., Williams, P.J., Rademacher, T.W. Journal of reproductive immunology 59: 267 – 275 (2003)